Copyright: ©Author(s) 2026.
World J Gastroenterol. Jun 14, 2026; 32(22): 118036
Published online Jun 14, 2026. doi: 10.3748/wjg.v32.i22.118036
Published online Jun 14, 2026. doi: 10.3748/wjg.v32.i22.118036
Table 2 Comparison of 5-aminosalicylic acid therapy outcomes between the female and male cohorts after 1:1 propensity score matching, n (%)
| Female cohort (n = 177) | Male cohort (n = 177) | aOR | 95%CI | P value | |
| Frequency of UC flare-ups per year | |||||
| ≤ 2 | 145 (81.9) | 110 (62.1) | 2.78 | 1.69-4.55 | < 0.001 |
| > 2 | 32 (18.1) | 67 (37.9) | |||
| EMR (n = 173) | 83 (46.9) | 90 (50.8) | 1.17 | 0.77-1.78 | 0.46 |
| EMH (n = 72) | 45 (25.4) | 29 (16.4) | 0.58 | 0.34-0.97 | 0.04 |
| Serious complications (n = 60) | 25 (14.1) | 35 (19.8) | 1.5 | 0.85-2.63 | 0.16 |
| Colectomy (n = 59) | 22 (12.4) | 37 (20.9) | 1.86 | 1.05-3.31 | 0.03 |
| Malignancies1 (n = 23) | 9 (5.1) | 14 (7.9) | 1.6 | 0.68-3.81 | 0.29 |
- Citation: Liu ZS, Tang H, Zhang HM, Bai XY, Yang H, Li XF, Qian JM. Sex-specific differences in the efficacy and prognosis of 5-aminosalicylic acid therapy for ulcerative colitis: A 20-year retrospective cohort study. World J Gastroenterol 2026; 32(22): 118036
- URL: https://www.wjgnet.com/1007-9327/full/v32/i22/118036.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i22.118036